NA
TEVA icon

NewEdge Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

NewEdge Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
37,994
-251
-0.7% -$8.36K ﹤0.01% 1498
2026
Q1 		$1.15M Sell
38,245
-8,088
-17% -$260K ﹤0.01% 1408
2025
Q4 		$1.45M Buy
46,333
+2,183
+5% +$53.8K 0.01% 1249
2025
Q3 		$892K Buy
44,150
+2,180
+5% +$38.3K ﹤0.01% 1460
2025
Q2 		$703K Buy
41,970
+7,384
+21% +$119K ﹤0.01% 1491
2025
Q1 		$532K Sell
34,586
-896
-3% -$16K ﹤0.01% 1552
2024
Q4 		$782K Buy
35,482
+3,983
+13% +$72.5K ﹤0.01% 1295
2024
Q3 		$568K Sell
31,499
-42
-0.1% -$735 ﹤0.01% 1399
2024
Q2 		$513K Buy
31,541
+21,484
+214% +$331K ﹤0.01% 1412
2024
Q1 		$142K Buy
10,057
+7,195
+251% +$90.7K ﹤0.01% 1944
2023
Q4 		$29.9K Buy
2,862
+113
+4% +$1.05K ﹤0.01% 2412
2023
Q3 		$28K Sell
2,749
-10,876
-80% -$101K ﹤0.01% 2281
2023
Q2 		$103K Buy
13,625
+1,687
+14% +$13.7K ﹤0.01% 1843
2023
Q1 		$106K Buy
11,938
+5,930
+99% +$58.6K ﹤0.01% 1740
2022
Q4 		$11.8K Buy
+6,008
New +$52.4K ﹤0.01% 2318
2017
Q3 		– Sell
-816
Closed -$25.4K – 1043
2017
Q2 		$25.4K Buy
+816
New +$25.3K ﹤0.01% 667

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

NewEdge Advisors's TEVA Position: Q2 2026 in Review

NewEdge Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 0.66% in Q2 2026, selling an estimated $8.36K and leaving 37,994 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

NewEdge Advisors first reported a position in TEVA in Q2 2017 and has held it in 16 quarters since. The position peaked at $1.45M in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • NewEdge Advisors held 37,994 shares of Teva Pharmaceuticals worth $1.29M as of Q2 2026.
  • NewEdge Advisors sold 251 Teva Pharmaceuticals shares in Q2 2026, an estimated $8.36K.
  • Teva Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #1498 holding.
  • NewEdge Advisors first reported a position in Teva Pharmaceuticals in Q2 2017 and has held it in 16 quarters since.
  • NewEdge Advisors's Teva Pharmaceuticals position peaked at $1.45M in Q4 2025.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.